Related Experiment Video

Updated: Jul 31, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control

F D Richard Hobbs1

  • 1Primary Care and General Practice, Primary Care Clinical Sciences Building, University of Birmingham, Edgbaston, UK.

International Journal of Cardiology
|November 18, 2005
PubMed

Insights

Patients with diabetes mellitus face higher cardiovascular disease (CVD) risks. Lipid-lowering therapy, particularly statins targeting low-density lipoprotein cholesterol (LDL-C), significantly reduces cardiovascular events in these individuals.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus significantly elevates cardiovascular disease (CVD) risk compared to the general population.
  • Dyslipidemia, characterized by abnormal lipid profiles, is a key modifiable risk factor in diabetic patients.
  • Key dyslipidemia features in type 2 diabetes include elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-C), and altered low-density lipoprotein cholesterol (LDL-C).

Purpose of the Study:

  • To evaluate the efficacy of lipid-lowering therapy in reducing cardiovascular risk in patients with diabetes mellitus.
  • To highlight the role of statins as a primary pharmacological intervention for dyslipidemia in type 2 diabetes.
  • To underscore the importance of managing dyslipidemia for primary and secondary CVD prevention in diabetic populations.

Main Methods:

  • Analysis of clinical trials focused on primary and secondary prevention of CVD in diabetic patients.
  • Review of data from statin trials specifically conducted in patients with type 2 diabetes without prior CVD.
  • Assessment of the impact of lipid-lowering agents on cardiovascular event reduction.

Main Results:

  • Lipid-lowering therapy demonstrably reduces cardiovascular risk in patients with type 2 diabetes.
  • A specific statin trial showed a 37% reduction in cardiovascular events with atorvastatin 10 mg compared to placebo in diabetic patients without prior CVD.
  • Low-density lipoprotein cholesterol (LDL-C) management is prioritized, with statins being the first-line pharmacological treatment.

Conclusions:

  • Lipid-lowering therapy is crucial for mitigating cardiovascular risk in patients with diabetes mellitus.
  • Statins are effective in reducing cardiovascular events and are the recommended first-line treatment for dyslipidemia in this population.
  • Ongoing and upcoming trials will further elucidate the benefits of lipid-modulating strategies for attenuating cardiovascular risk in diabetic individuals.

More Related Videos

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...